<DOC>
	<DOCNO>NCT00059228</DOCNO>
	<brief_summary>This study evaluate efficacy estrogen treatment woman postpartum depression ( PPD ) . PPD cause significant distress large number woman ; demand effective therapy treat PPD considerable . Estradiol therapy prophylactic effect woman high risk develop PPD . The prevention decline estradiol level may prevent onset PPD . Studies also suggest estradiol antidepressant effect woman may provide safe effective alternative traditional antidepressant woman PPD . Participants screen medical history , physical examination , blood urine test , psychological test , genetic study , self-rating scale questionnaire . Upon study entry , woman randomly assign wear skin patch contain either estradiol placebo ( patch active ingredient ) 6 week . Women receive estradiol menstruate last week study receive progesterone 7 day initiate menstruation . Women receive placebo menstruate last week study continue receive placebo end study . Every week , participant blood take ask complete symptom self-rating scale . A urine sample blood sample collect different time point study . Participants receive placebo whose symptom improve estradiol therapy offer treatment standard antidepressant medication 8 week end study .</brief_summary>
	<brief_title>Clinical Trial Estrogen Postpartum Depression</brief_title>
	<detailed_description>Postpartum-related mood disorder cause significant distress potentially large number woman . The demand effective therapy treat mood disorder considerable , need define clinical biologic marker may predict successful response mood disturbance estradiol . Despite prevalence postpartum depression , double-blind , control trial antidepressant agent perform condition ( 1-4 ) - two placebo-controlled . A recent large multicenter trial fail confirm initially promising anecdotal report protective role fish oil PPD ( 5 ) . Similarly , despite evidence estradiol therapeutic efficacy trial open ( monotherapy ) ( 6 ) control ( combine traditional antidepressant agent ( 7 ) ) , potential estradiol effective alternative traditional psychotropics postpartum depression examine controlled condition . Postpartum depression occur definition delivery woman relatively hypogonadal . Indeed , plasma estradiol progesterone level low comparable see peri postmenopause . However , evidence postpartum depression represent simple hormone deficiency , woman postpartum depression distinguish woman without postpartum depression basis abnormality basal reproductive hormone . Nonetheless , role decline estradiol secretion suggest following observation : 1 ) estradiol therapy report prophylactic effect woman high risk develop postpartum depression ( 8 ) , suggest prevention decline estradiol level ( threshold rate decline ) may prevent onset postpartum depression woman ; ( 2 ) decline ovarian steroid trigger onset mood disturbance woman woman without history postpartum depression scale model pregnancy puerperium ( 9 ) . Thus , depression occur perimenopause , ovarian hormone secretion also decline , postpartum depression may also responsive estradiol therapy . In fact , open trial estradiol therapy postpartum depression ( 6 ) well trial estradiol combination traditional antidepressant ( 7 ) suggest estradiol antidepressant-like effect observe within three week time period woman postpartum onset major depression . Thus , estradiol treatment may provide safe effective alternative traditional antidepressant woman postpartum depression , may also suggest relevant hormonal trigger development condition . In protocol wish investigate effect estradiol mood woman moderately severe postpartum depression placebo control condition . This protocol address follow question : 1 ) Does estradiol improve mood postpartum depress woman ?</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . A history least two week postpartumrelated mood disturbance moderate severity , selfreport onset depression within three month normal vaginal delivery uncomplicated Caesarean section ; 2 . A current episode minor ( meet 34 criterion symptom ) major depression ( moderate severity less SCID severity scale meeting DSMIV criterion symptom 9 [ suicidal ideation ] ) determine administration minor depression module SADSL Structured Clinical Interview DSMIV . Additionally , ensure subject meet minimum threshold severity depression , subject score great equal 10 either Beck Depression Inventory ( BDI ) Center Epidemiologic Studies Depression ( CESD ) Scale least three six clinic visit two week screen phase , well 17 item Hamilton Depression score great equal 10 . Subjects exclude meet follow criterion : major depression great moderate severity ( include postpartum psychosis ) . DSMIV criterion # 9 ( suicidal ideation ) , anyone require immediate treatment clinical assessment . 3 . Not great six month post delivery ; 4 . Age 20 45 ; 5 . In good medical health , take medication dietary herbal supplement regular basis ( exception multivitamins calcium supplement ) . EXCLUSION CRITERIA : The following condition constitute contraindication treatment preclude subject participation protocol : 1. severe major depression follow : positive ( threshold ) response SCID major depression section item # 9 , suicidal ideation ; anyone require immediate treatment clinical assessment ; severity rating great moderate SCID IV interview ( include postpartum psychosis ) ; 2. current treatment antidepressant medication 3. history psychiatric illness two year report onset current episode depression history either mania ( DSMIV criterion ) postpartum psychosis time past . 4. history ischemic cardiac disease , pulmonary embolism , retinal thrombosis , thrombophlebitis ; subject risk factor thromboembolic phenomenon include cigarette smoker ( great 10 cigarette per day ) , varicose vein , patient prolong period immobilization ( include prolong travel ) , active heart disease . 5. renal disease , asthma 6. hepatic dysfunction 7. woman history carcinoma breast , woman family history following : premenopausal breast cancer bilateral breast cancer first degree relative ; multiple family member ( great three relative ) postmenopausal breast cancer 8. woman history uterine cancer , endometriosis , illdefined pelvic lesion , particularly undiagnosed ovarian enlargement , undiagnosed vaginal bleeding 9. patient know hypersensitivity estradiol , transdermal skin patch , medroxyprogesterone acetate 10. pregnant woman 11. porphyria 12. diabetes mellitus 13. cholecystitis pancreatitis 14. history cerebrovascular disease ( stroke ) , epilepsy , hypertension , hypercalcemia 15. recurrent migraine headaches 16. malignant melanoma 17. history familial hyperlipoproteinemia 18. prior hormonal therapy treatment postpartumrelated mood physical symptom within last six month 19. history psychiatric illness two year prior report onset current episode depression</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 15, 2016</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Gonadal Steroids</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Puerperium</keyword>
	<keyword>Depression</keyword>
	<keyword>Postpartum</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Estrogen Response Element</keyword>
	<keyword>Postpartum Depression</keyword>
</DOC>